Does dapagliflozin regress left ventricular hypertrophy in patients with type 2 diabetes? A prospective, double-blind, randomised, placebo-controlled study.
Alexander J M BrownChim LangRory McCrimmonAllan D StruthersPublished in: BMC cardiovascular disorders (2017)
Clinical Trials.gov: NCT02956811 . Registered November 2016.
Keyphrases
- double blind
- clinical trial
- left ventricular
- placebo controlled
- phase ii
- phase iii
- study protocol
- heart failure
- open label
- hypertrophic cardiomyopathy
- acute myocardial infarction
- cardiac resynchronization therapy
- mitral valve
- aortic stenosis
- left atrial
- randomized controlled trial
- acute coronary syndrome
- atrial fibrillation
- catheter ablation